Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction
NCT ID: NCT00574756
Last Updated: 2019-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
14 participants
INTERVENTIONAL
2007-12-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
NCT01505179
RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain
NCT03257683
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
NCT03953989
Ranolazine in Diastolic Heart Failure
NCT01163734
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
NCT01887353
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
ranolazine
extended release 500 mg twice a day for two weeks
2
Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
ranolazine
extended release 500 mg twice a day for two weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranolazine
extended release 500 mg twice a day for two weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Preserved systolic function
* NYHA Class I-II
Exclusion Criteria
* Taking medications that prolong QT interval or are potent inhibitors of CYP3A
* Significant coronary artery disease
* Severe valvular disease
* Hepatic disease
* Severe kidney disease
* Women of childbearing age
* Prior serious ventricular arrhythmia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony DeMaria, MD
Role: PRINCIPAL_INVESTIGATOR
UCSD Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Medical Center
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
070480
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.